Novel semi-synthetic carbohydrates as potential therapeutics for severe malaria
Lead Research Organisation:
University of Liverpool
Department Name: Sch of Biological Sciences
Abstract
Severe malaria is a disease that kills millions every year, especially in developing nations, resulting in widespread suffering and economic damage. Severe malaria is caused by both the aggregation of red blood cells infected by the parasite into rosettes and via cytoadherence, the attachment of red blood cells to the cells of the host, lining the blood vessels. Rosette formation and cytoadherence both prevent proper transport of oxygen by the red blood cells around the capilaries of the brain and causes blockages, damaging the brain, and this is often fatal. This project will identify the simplest fragments, from a novel semi-synthetic library of negatively charged carbohydrates, that are able to disrupt rosetting and cytoadherence while minimising/eliminating any potential side-effects. This will provide information concerning the minimum structures required, allowing cheap, chemical synthesis of the molecules to be undertaken. This project will ultimatley lead to the development of new pharmaceutical agents, which are urgently needed, as resistance emerges to the drugs being administered currently.
Technical Summary
Malaria, caused by Plasmodium species, affects one third of the world?s population with over 300 million infections resulting in 2 million deaths annually. Severe malaria, caused by P. falciparum, is the most serious complication of the disease resulting in widespread suffering and economic damage, especially in developing nations. Severe malaria severity correlates with the extent of venule occlusion (by rosetting, auto-aglutination and cytoadherance) resulting in hypoxia and coma. Cell-cell adhesions are facilitated by interactions between parasite expressed proteins and host carbohydrates (hyaluronic acid, chondroitin sulfate, heparan sulfate) and proteins (CD-36, E-selectin, PECAM-1, ICAM-1, VCAM-1 and thrombospondin) while the rosetting process is mediated principally by the parasite expressed protein, P. falciparum erythrocyte membrane protein-1 (PfEMP-1) through attachment to host cell-surface carbohydrates. It has been shown that both naturally occuring and chemically modified carbohydrates are capable of disrupting malaria rosettes and/or cytoadherance, but the structural details of these interactions, and the carbohydrates themselves, remain poorly defined. This project will create an arsenal of semi-synthetic, structurally diverse polysaccharides which will faciitate the generation of a series of size-defined, structurally diverse oligosaccharides from which the simplest structures (i.e. smallest and least charged) capable of inhibiting rosetting and cytoadherence will be selected, purified and their detailed structures defined by a combination of recently developed sequencing techniques (e.g. ES-MS and NMR). As a precaution, successful inhibitors will also be screened for potential side-effects, including the formation of immunogenic platelet factor-IV complexes and activities with the blood clotting cascade (anti-factor Xa, antithrombin and factor II) activities, which can be highly attenuated (down to 0.5 %) with simple chemical modifications. The structural information will not only provide detailed data concerning the nature of the interacting species, leading to improved mechanistic understanding, but will also provide the structurally simplest targets for future chemical synthesis, the first step to producing new pharmaceutical agents.
Publications



Skidmore M
(2015)
Inhibition of influenza H5N1 invasion by modified heparin derivatives
in MedChemComm

Skidmore MA
(2017)
A semi-synthetic glycosaminoglycan analogue inhibits and reverses Plasmodium falciparum cytoadherence.
in PloS one

Skidmore MA
(2017)
A semi-synthetic glycosaminoglycan analogue inhibits and reverses Plasmodium falciparum cytoadherence.
in PloS one

Tree JA
(2021)
Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.
in British journal of pharmacology
Description | The interaction of the SARS CoV-2 spike protein receptor binding domain with heparin and its derivatives. |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Our study of the interaction of the SARS CoV-2 spike protein receptor binding domain with heparin and its derivatives, both as models of the cell surface ligand, heparan sulfate, and as potential therapeutics, underpinned the international CHARTER (Can nebulised heparin reduce time to extubation in SARS-CoV-2?) clinical trial. Our work was published originally in March 2020 on the BioRiv server [1], then in the peer-reviewed journal, Thrombosis and Haemostasis [2], and underpins both the present Wellcome Trust application as well as a recent application to NIHR. The protocol [3], which was adopted for CHARTER, also involved several of the applicants as well as an international group of collaborating clinicians. Now, the findings of the CHARLI (Can heparin administration reduce lung injury?) clinical trial, conducted by the same international group of collaborators, have been published in Lancet Respiratory Medicine ('Nebulised heparin for patients with or at risk of acute respiratory distress syndrome; a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.' by B Dixon et al., [4]. The results from CHARLI confirm the safety of nebulised heparin for the treatment of non-viral ARDS, indicating a reduction in the extent of lung damage, while enabling an earlier return home than patient control groups. Since the publication by Dixon et al., there has been enthusiasm among the scientific community to test nebulised heparin in a more homogenous population than was used in the initial study, since ARDS can take many forms; a view echoed in a recent publication in The Lancet Respiratory Medicine [5]. Very recently, a study in the BMJ [6] has shown that early prophylaxis with heparin decreases the 30-day mortality in a cohort of COVID-19 patients who had no increased risk of serious bleeding events, a risk factor for the use of conventional heparin. These findings provide further confidence in the possible application of better-optimised compounds derived from crude heparin, a source of greater structural and bioactivity diversity than the conventional pharmaceutical heparin employed in the CHARLI clinical trial, and ones from which bleeding complications can be essentially eliminated. [1] https://doi.org/10.1101/2020.02.29.971093 [2] Thromb Haemost 2020; 120(12): 1700-1715 DOI: 10.1055/s-0040-1721319 [3] https://doi.org/10.1101/2020.04.28.20082552 [4] DOI: 10.1016/S2213-2600(20)30470-7 [5] https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30513-0/fulltext [6] https://www.bmj.com/content/372/bmj.n311 |
Description | project grant |
Amount | £50,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2010 |
End | 09/2011 |
Title | sulfated polysaccharide library |
Description | a family of sulfated polysaccharides with several interesting biological activities in addition to those of the grant also developed several assays |
Type Of Material | Technology assay or reagent |
Year Produced | 2008 |
Provided To Others? | Yes |
Impact | assays measuring inhibition of viral attachment are underway |
Description | Collaboration in infectivity studies with University of Keele |
Organisation | Keele University |
Department | School of Life Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provision of sulfated inhibitors of parasite invasion |
Collaborator Contribution | Assays of invasion |
Impact | Publication in preparation |
Start Year | 2009 |
Description | Cytoadherence and inhibition with polysaccharides |
Organisation | Liverpool School of Tropical Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provide polysaccharides to inhibit and reverse cytoadherence |
Collaborator Contribution | Provided assay for cytoadherence |
Impact | paper in preparation: Reversal and Inhibition of P.falciparum cytoadherence by chemically modified polysaccharide analogues of glycosaminoglycans.M. Khairul, M.A.Skidmore, A.C.Craig and E.A.Yates (in preparation) |
Start Year | 2009 |
Description | inhibitors of viral attachment |
Organisation | San Raffaele Hospital |
Department | Virology |
Country | Italy |
Sector | Hospitals |
PI Contribution | Provided inhibitors of viral attachment and invasion |
Collaborator Contribution | provided assays of viral entry into cells |
Impact | Inhibition of influenza H1N1 viral entry into cells. A. Ruzentska, M.A.Skidmore, E.A.Yates and E.Vicenzi |
Start Year | 2008 |
Description | ICOPA Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | 100 + audience with questions and enquiries Useful exchange of know-how and materials. ICOPA XII, Melbourne Australia, 15/08/12-20/08/10 (www.icopaxii.org) |
Year(s) Of Engagement Activity | 2010 |
Description | Invited Talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Poster Presentation |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | 6th International Conference on proteoglycans, Aix-les-Bains, France. "GAG analogues disrupt P.falciparum malaria" 13th-17th September 2009. (http://pg2009-fr/.Aix-les-Bains) new collaborative links |
Year(s) Of Engagement Activity | 2009 |
Description | Invited talk to University of New South Wales |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Audience questions answered and potential collaborative links formed University of New South Wales, Australia (2010) "GAGs, Chemically Modified derivatives and Semi-synthetic analogues: new technologies paving the way towards glycotherapies". Interest from potential new collaborators. |
Year(s) Of Engagement Activity | 2010 |
Description | Outreach presentation to public at 68th Annual Meeting of SBPC (in Porto Seguro, Bahia, Brazil, 2016) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Engaged with broad general public in Brazil over 1 week, demonstrating structures of biological materials using simple experiments and outlining infection processes in tropical diseases using easy to follow diagrams. |
Year(s) Of Engagement Activity | 2016 |
URL | http://sbpcacervodigital.org.br/handle/20.500.11832/96 |
Description | RSC invited talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Invited Talk. Royal Society of Chemistry Autumn Meeting of the Carbohydrate Group, Liverpool, 13th-17th september 2011. (www.rsc.org/ConferncesAndEvents) New experimental design formed following discussions, which has been conducted by undergraduate research students. |
Year(s) Of Engagement Activity | 2011 |
Description | Talk to visiting medical students from Saudi Arabia |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Medical Students from Saudi Arabia were given a talk about potential treatments for malaria based on carbohydrates. Several expressed interest in studying in UK |
Year(s) Of Engagement Activity | 2009 |
Description | invited talk keele |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | NEMO EU-Marie Curie Actions, ITN Network-, University of Keele, 13-17/09/12. "Prebiotics and probiotics in medicine, veterinary sciences and aquaculture: the future" (www.keele-conferencemanagement.com/nemo.2012) Collaboration with Brazilian research group initiated |
Year(s) Of Engagement Activity | 2012 |
URL | http://www.keele-conferencemanagement.com/nemo.2012 |